The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve ...

Efficacy and safety of endoscopic retrograde cholangiopancreatography (ERCP) vs percutaneous transhepatic biliary drainage (PTBD) for cholangiocarcinoma biliary obstruction: An updated systematic ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

The following is a summary of “A potential inflammatory biomarker for advanced endometrial cancer treated with lenvatinib plus pembrolizumab,” published in the December 2024 issue of Obstetrics and ...

In the CLEAR trial, lenvatinib + pembrolizumab demonstrated significant improvement in PFS (24 months versus 9 months; HR 0.39, 95% CI 0.32-0.49), OS (not reached in either arm; HR 0.66, 95% CI 0.49-0 ...